Log In
Print
BCIQ
Print
Print this Print this
 

E2609

  Manage Alerts
Collapse Summary General Information
Company Eisai Co. Ltd.
DescriptionBeta-site APP-cleaving enzyme (BACE) inhibitor
Molecular Target Beta-site APP-cleaving enzyme 1 (BACE1)
Mechanism of ActionBeta-site APP-cleaving enzyme 1 (BACE1) inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD)
Regulatory Designation
Partner Biogen Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

$100.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today